To access the full text documents, please follow this link: http://hdl.handle.net/2445/124277

Title:	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG)
Author:	Kovacs, Gabor G.; Xie, Sharon X.; Lee, Edward B.; Robinson, John L.; Caswell, Carrie; Irwin, David J.; Toledo, Jon B.; Johnson, Victoria; Smith, Douglas H.; Alafuzoff, Irina; Attems, Johannes; Bencze, Janos; Bieniek, Kevin F.; Bigio, Eileen H.; Bodi, Istvan; Budka, Herbert; Dickson, Dennis W.; Dugger, Brittany N.; Duyckaerts, Charles; Ferrer, Isidro (Ferrer Abizanda); Forrest, Shelley L.; Gelpi, Ellen; Gentleman, Stephen M.; Giaccone, Giorgio; Grinberg, Lea T.; Halliday, Glenda M.; Hatanpaa, Kimmo J.; Hof, Patrick R.; Hofer, Monika; Hortobágyi, Tibor; Ironside, James W.; King, Andrew; Kofler, Julia; Kövari, Enikö; Kril, Jillian J.; Love, Seth; Mackenzie, Ian R.; Mao, Qinwen; Matej, Radoslav; McLean, Catriona; Muñoz, David G.; Murray, Melissa E.; Neltner, Janna; Nelson, Peter T.; Ritchie, Diane; Rodriguez, Roberta D.; Rohan, Zdenek; Rozemüller, Annemieke; Sakai, Kenji; Schultz, Christian; Seilhean, Danielle; Smith, Vanessa; Tacik, Pawel; Takahashi, Hitoshi; Takao, Masaki; Thal, Dietmar Rudolf; Weis, Serge; Wharton, Stephen B.; White III, Charles L.; Woulfe, John M.; Yamada, Masahito; Trojanowski, John Q.
Notes:	Aging-related tau astrogliopathy (ARTAG) is a recently introduced terminology. To facilitate the consistent identification of ARTAG and to distinguish it from astroglial tau pathologies observed in the primary frontotemporal lobar degeneration tauopathies we evaluated how consistently neuropathologists recognize (1) different astroglial tau immunoreactivities, including those of ARTAG and those associated with primary tauopathies (Study 1); (2) ARTAG types (Study 2A); and (3) ARTAG severity (Study 2B). Microphotographs and scanned sections immunostained for phosphorylated tau (AT8) were made available for download and preview. Percentage of agreement and kappa values with 95% confidence interval (CI) were calculated for each evaluation. The overall agreement for Study 1 was > 60% with a kappa value of 0.55 (95% CI 0.433-0.645). Moderate agreement (> 90%, kappa 0.48, 95% CI 0.457-0.900) was reached in Study 2A for the identification of ARTAG pathology for each ARTAG subtype (kappa 0.37-0.72), whereas fair agreement (kappa 0.40, 95% CI 0.341-0.445) was reached for the evaluation of ARTAG severity. The overall assessment of ARTAG showed moderate agreement (kappa 0.60, 95% CI 0.534-0.653) among raters. Our study supports the application of the current harmonized evaluation strategy for ARTAG with a slight modification of the evaluation of its severity.
Subject(s):	-Malalties del sistema nerviós -Envelliment -Nervous system diseases -Aging
Rights:	(c) American Association of Neuropathologists, 2017
Document type:	Article Article - Accepted version
Published by:	Oxford University Press
Share:

Show full item record